SCHEMBL5842470

SCHEMBL5842470

CN(C)c1ccc(NC(=O)C2CC(=O)N(c3ccc4ccccc4c3)C2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.74
ALDH1A1 P00352 4/20 0.74
SMN1; SMN2 Q16637 3/20 0.74
KDM4E B2RXH2 1/20 0.74
HPGD P15428 1/20 0.74
MCL1 Q07820 1/20 0.74
HIF1A Q16665 1/20 0.74
NPSR1 Q6W5P4 1/20 0.74
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
POLB P06746 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA4 P22748 1/20 0.52
CA6 P23280 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA13 Q8N1Q1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5843350 0.87 MAPT (0.72) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL5842703 0.84 MAPT (0.57) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL6625375 0.83 MAPT (0.52) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL5843355 0.80 SMN1; SMN2 (0.69) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL5842320 0.80 SMN1; SMN2 (0.69) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL5842314 0.78 SMN1; SMN2 (0.66) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL5841897 0.76 ALDH1A1 (0.58) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL5844742 0.76 ALDH1A1 (0.67) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL5844411 0.76 ALDH1A1 (0.72) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL5842375 0.76 TSHR (0.64) MAPTHPGDKMT2APOLBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R MAPT 4395/4885ALDH1A1 3034/4885SMN1; SMN2 3678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.